

Charles Chuah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2794574/publications.pdf>

Version: 2024-02-01

69
papers

3,172
citations

304743

22
h-index

161849

54
g-index

69
all docs

69
docs citations

69
times ranked

3582
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2333-2340. | 1.6 | 724 |
| 2 | Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404. | 1.4 | 392 |
| 3 | Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-237. | 1.6 | 356 |
| 4 | BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442. | 16.8 | 292 |
| 5 | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621. | 10.7 | 214 |
| 6 | Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. <i>Nature Genetics</i> , 2014, 46, 245-252. | 21.4 | 97 |
| 7 | Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1835-1850. | 7.2 | 97 |
| 8 | Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050. | 1.4 | 95 |
| 9 | CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. <i>Cancer Cell</i> , 2016, 30, 792-805. | 16.8 | 86 |
| 10 | Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , 2017, 123, 2875-2880. | 4.1 | 79 |
| 11 | Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 152-164. | 11.1 | 58 |
| 12 | Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). <i>Blood</i> , 2014, 124, 152-152. | 1.4 | 55 |
| 13 | An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. <i>Blood</i> , 2020, 135, 2337-2353. | 1.4 | 49 |
| 14 | Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. <i>Cancer</i> , 2017, 123, 4851-4859. | 4.1 | 45 |
| 15 | Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833. | 7.2 | 43 |
| 16 | Pyruvium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. <i>Oncotarget</i> , 2015, 6, 33769-33780. | 1.8 | 40 |
| 17 | Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4348-4369. | 6.4 | 37 |
| 18 | An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Stauf2 as a key regulator of myeloid leukemia. <i>Nature Cancer</i> , 2020, 1, 410-422. | 13.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519. | 1.4 | 30 |
| 20 | Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, e551-e554. | 3.5 | 27 |
| 21 | Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 41-42. | 1.4 | 27 |
| 22 | Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. <i>Blood</i> , 2011, 118, 109-109. | 1.4 | 27 |
| 23 | Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1589-1599. | 2.5 | 21 |
| 24 | An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. <i>Blood</i> , 2015, 126, 827-827. | 1.4 | 17 |
| 25 | Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1702-1712. | 4.1 | 14 |
| 26 | Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia. <i>Translational Oncology</i> , 2019, 12, 1221-1228. | 3.7 | 13 |
| 27 | Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7084-7084. | 1.6 | 13 |
| 28 | Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7002-7002. | 1.6 | 13 |
| 29 | SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 1787-1798. | 7.2 | 12 |
| 30 | Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. <i>Blood</i> , 2011, 118, 2767-2767. | 1.4 | 12 |
| 31 | Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. <i>Experimental Hematology</i> , 2016, 44, 189-193.e2. | 0.4 | 11 |
| 32 | Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. <i>Blood</i> , 2020, 136, 43-44. | 1.4 | 11 |
| 33 | Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7081-7081. | 1.6 | 10 |
| 34 | Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. <i>International Journal of Hematology</i> , 2021, 114, 65-78. | 1.6 | 9 |
| 35 | The arginase inhibitor N ^ε -hydroxy-L-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. <i>PLoS ONE</i> , 2018, 13, e0205254. | 2.5 | 8 |
| 36 | Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2010, 116, 3292-3292. | 1.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. <i>Blood</i> , 2021, 138, 2550-2550. | 1.4 | 8 |
| 38 | Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. <i>Blood</i> , 2015, 126, 4025-4025. | 1.4 | 7 |
| 39 | Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012, 120, 3747-3747. | 1.4 | 6 |
| 40 | Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2013, 122, 4007-4007. | 1.4 | 6 |
| 41 | Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7002-7002. | 1.6 | 6 |
| 42 | Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up. <i>Blood</i> , 2017, 130, 896-896. | 1.4 | 6 |
| 43 | <i>BIM</i> deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 234-237. | 1.3 | 5 |
| 44 | The EUTOS Score Is Highly Predictive for Clinical Outcome and Survival in Asian Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib. <i>Blood</i> , 2012, 120, 3758-3758. | 1.4 | 5 |
| 45 | The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. <i>Blood</i> , 2015, 126, 480-480. | 1.4 | 5 |
| 46 | PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6503-6503. | 1.6 | 5 |
| 47 | Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, 24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2013, 122, 2743-2743. | 1.4 | 5 |
| 48 | Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). <i>Blood</i> , 2013, 122, 1496-1496. | 1.4 | 4 |
| 49 | Use of Immunoglobulin Infusions in the Management of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5097-5097. | 1.4 | 3 |
| 50 | EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7023-7023. | 1.6 | 3 |
| 51 | Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline <i>BCR-ABL1</i> Level and Baseline Mutation Status in the Optic Trial. <i>Blood</i> , 2021, 138, 307-307. | 1.4 | 3 |
| 52 | Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. <i>Anti-Cancer Drugs</i> , 2021, 32, 526-536. | 1.4 | 2 |
| 53 | The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.. <i>Blood</i> , 2010, 116, 3410-3410. | 1.4 | 2 |
| 54 | Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3749-3749. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. <i>Blood</i> , 2013, 122, 2738-2738. | 1.4 | 2 |
| 56 | Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18052-e18052. | 1.6 | 2 |
| 57 | Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia. <i>Leukemia</i> , 2022, 36, 892-896. | 7.2 | 2 |
| 58 | Dual Specific Inhibitors Of The BCR-ABL and MNK Kinases As Potential Therapeutics For Blast Crisis Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2702-2702. | 1.4 | 1 |
| 59 | High Response and Complete Remission Rates in Relapsed/Refractory Multiple Myeloma Treated with Bortezomib, Thalidomide, Dexamethasone and Zoledronic Acid (VTD-Z) Combination Therapy.. <i>Blood</i> , 2005, 106, 5127-5127. | 1.4 | 1 |
| 60 | The BCL-2 Inhibitor ABT-199 Enhances Imatinib-Induced Cell Death In Chronic Phase CML Progenitors. <i>Blood</i> , 2013, 122, 3978-3978. | 1.4 | 1 |
| 61 | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2863. | 4.1 | 1 |
| 62 | The Chronic Anemia. , 2004, , 571-580. | | 0 |
| 63 | Nutritional Anemias. , 2004, , 559-570. | | 0 |
| 64 | Factors Influencing Responsiveness to Bortezomib in Patients with Multiple Myeloma Suggest a Possible Role for Host Immunocompetency.. <i>Blood</i> , 2006, 108, 5100-5100. | 1.4 | 0 |
| 65 | Physiologic Hypoxia Promotes Maintenance of CML Stem Cells Despite Effective BCR-ABL Inhibition. <i>Blood</i> , 2011, 118, 450-450. | 1.4 | 0 |
| 66 | A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 1666-1666. | 1.4 | 0 |
| 67 | Post hoc analysis of sustained efficacy/tolerability of 12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7066-7066. | 1.6 | 0 |
| 68 | The BIM Deletion Polymorphism: A Paradigm Of a Permissive Interaction Between Germline and Acquired TKI Resistance Factors In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3977-3977. | 1.4 | 0 |
| 69 | Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. <i>Blood</i> , 2015, 126, 5142-5142. | 1.4 | 0 |